MD Biosciences launches Neurology Discovery Services

Share Article

MD Biosciences adds in vivo models for Alzheimer’s and Pain with the launch of its Neurology Discovery Services located in Israel.

Herzelia-Pituah, Israel (PRWEB) May 24, 2006 -- MD Biosciences, a global biotechnology company focused in inflammations research, announced today that it has expanded its Israel facility with the launch of its Neurology Discovery Services. The expanded laboratory in Israel provides the necessary capacity to accommodate the company’s growing service portfolio, adding additional models for Multiple Sclerosis and launching new models for Alzheimer’s disease, Nociception, Neuropathic and Inflammatory Pain. The rising number of pharmaceutical and biotechnology companies working within drug discovery and the strong emphasis on outsourcing increases MD Biosciences market potential.

MD Biosciences launched its operations in 1998 with a focus in rheumatoid arthritis products and services and has since added the Inflammations Discovery Service to include a broad range of models for RA, Asthma, IBD/Crohn’s, Diabetes and MS along with the Senerga Platform for mechanism of action studies. “The launch of the Neurology Discovery Services laboratory in Israel directly compliments and strengthens the resources available to MD Biosciences' clients by providing a range of solutions for Neurological Diseases. This capability, together with our strong service portfolio from the Inflammations Discovery Service, will strengthen MD Biosciences' position even further, putting us at the cutting edge of drug discovery contract research.” comments Eddie Moradian, PhD. and Managing Director.

Dr Sigal Meilin, having extensive background and experience in the design and performance of neurological disease models, joins MD Biosciences Israel as the director of the Neurology Discovery Services. Dr Meilin received her PhD from the University of Bar Ilan, Israel, and performed post-doctoral research related to Alzheimer’s disease and inflammation at the Tel Aviv University. Prior to joining MD Biosciences, Dr. Meilin was Associate Director of pharmacology and head of histology at an innovative drug discovery firm in Israel.

About MD Biosciences

MD Biosciences provides the most advanced products and pre-clinical services for pharmaceutical and biotechnology companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of internationally recognized scientific experts provides pharmaceutical and biotechnology companies’ in-depth expertise and technologies to tackle problems and provide total drug discovery solutions, enabling smarter results faster.

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Amy Clausen
Visit website